180340-70-9

Basic information

• Product Name: METHYL 6-AMINO-5-BROMONICOTINATE
• Synonyms: METHYL 2-AMINO-3-BROMO-5-PYRIDINECARBOXYLATE;METHYL 6-AMINO-5-BROMONICOTINATE;Methyl 6-amino-5-bromopyridine-3-carboxylate;Methyl 6-amino-5-bromopyridine-3-carboxylate, Methyl 2-amino-3-bromopyridine-5-carboxylate;Methyl 2-amino-3-bromopyridine-5-carboxylate;3-Pyridinecarboxylic acid, 6-aMino-5-broMo-, Methyl ester;Methyle6-amino-5-bromonicotinate
• CAS NO: 180340-70-9
• Molecular Formula: C7H7BrN2O2
• Molecular Weight: 231.05
• Product Categories: Amines;blocks;Bromides;Carboxes;Pyridines;Esters;Pyridine
• Mol File: 180340-70-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 166-168
• Boiling Point: 323.691 °C at 760 mmHg
• Flash Point: 149.563 °C
• Appearance: Brown/Powder
• Density: 1.662 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.02±0.49(Predicted)
• CAS DataBase Reference: METHYL 6-AMINO-5-BROMONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-AMINO-5-BROMONICOTINATE(180340-70-9)
• EPA Substance Registry System: METHYL 6-AMINO-5-BROMONICOTINATE(180340-70-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 180340-70-9(Hazardous Substances Data)

Usage

General Description

Methyl 6-amino-5-bromonicotinate, also known as 5-bromo-6-aminonicotinic acid methyl ester, is a chemical compound with the molecular formula C7H7BrN2O2. It is a derivative of nicotinic acid, a B vitamin, and is often used in pharmaceutical and organic synthesis processes. Methyl 6-amino-5-bromonicotinate contains a bromine atom and an amino group on the nicotinic acid ring, and the methyl ester group allows for easier handling and manipulation in the laboratory. Methyl 6-amino-5-bromonicotinate has potential applications in drug discovery and development due to its structural similarity to other bioactive molecules.

Upstream product

• 3167-49-5 6-aminonicotinic acid 
• 36052-24-1 methyl 6-aminonicotinoate 
• 180340-69-6 6-Amino-5-bromopyridine-3-carboxylic acid 

Downstream Products

• 180340-69-6 6-Amino-5-bromopyridine-3-carboxylic acid 
• 1227165-02-7 C₂₇H₂₄ClN₅O₂ 
• 1227243-17-5 C₂₆H₂₅ClN₄O₄ 
• 1227243-20-0 1-{5-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-azetidine-2-carboxylic acid 
• 1227243-08-4 1-{5-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-3-ethyl-urea 
• 1227165-01-6 4-[8-(3-chloro-phenyl)-6-methoxycarbonyloxymethyl-2-methyl-imidazo[1,2-a]pyridin-3-yl]-4H-pyridine-1-carboxylic acid methyl ester 
• 1227243-16-4 N-{5-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-2-dimethylamino-acetamide 
• 1227243-18-6 {5-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-carbamic acid ethyl ester 
• 1227165-36-7 ({5-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-methyl-amino)-acetic acid 
• 1227165-00-5 {4-[8-(3-chloro-phenyl)-2-methyl-imidazo[1,2-a]pyridin-6-ylmethyl]-phenyl}-urea 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS

-